CVS says specialty drug spend to quadruple

Share this article:
CVS say specialty drug spend to quadruple
CVS say specialty drug spend to quadruple

CVS/Caremark, the PBM, presented another perspective on the industry's increased focus on specialty medications: cost.

The pharmacy drug benefit manager projected consumer spending on treatments for diseases including cancer, immune deficiencies and multiple sclerosis will total $402 billion a year by 2020, a four-fold increase. While drug development does not necessarily trigger use, IMS Health's projections veer in the same direction: the research firm expects oncology drug sales will be between $74 billion and $84 billion in developed markets by 2017. As noted by IMS and CVS, specialty drugs usually require add-on costs, like being administered in a hospital or at a doctor's office.

CVS noted that specialized medicines are of particular note because only 4% of patients are responsible for the expected $402 billion in specialty medications costs. To tamp down on costs, CVS recommends implementing step-therapy requirements in which patients must first try lower-cost interventions before jumping to high-priced therapies.

Because treatment costs vary by field, eliminating a type of treatment—for example, infusions or all-oral therapies —will not reduce costs. Among the examples: oral MS drug Tecfidera costs $56,000 a year, and infused MS drug Tysabri rolls in at $53,000 a year, whereas infused cancer drug Herceptin costs $70,000 compared to the oral Gleevec, which costs $92,000 annually.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.